Core Viewpoint - The company has submitted a confidential F-1 registration statement to the U.S. Securities and Exchange Commission for a proposed dual listing in the U.S., which is a significant step in its global strategy and is expected to bring multiple positive impacts [1] Group 1: Global Financing and Market Expansion - The dual listing is anticipated to expand the company's global financing channels by entering one of the largest and most comprehensive capital markets, potentially attracting more long-term international investors focused on biotechnology and healthcare [1] - This move is expected to provide strong capital support for the company's future research and commercialization efforts [1] Group 2: Brand and Market Presence - Listing on NASDAQ is expected to enhance the company's international brand influence, improving its corporate image and industry recognition in global markets [1] - It will also increase opportunities for communication and collaboration with potential global partners, clients, and regulatory bodies [1] Group 3: Share Liquidity and Valuation - The establishment of a cross-market trading mechanism is likely to broaden the investor base and enhance overall share liquidity [1] - This international pricing environment is expected to better reflect the company's long-term value [1] Group 4: Governance and Compliance - Adhering to U.S. securities regulations and disclosure requirements is projected to improve the company's governance standards and operational transparency [1] - This will strengthen the company's compliance image and investor trust on a global scale [1] Group 5: Strategic Flexibility - The dual listing structure will provide the company with a richer platform for capital operations and strategic options for future international collaborations, mergers, and business expansions [1]
华检医疗(01931.HK)：已向美国证交会保密提交F-1表格登记声明草案